Home/Investors/Abingworth

Abingworth

Biotech Investor · 6 portfolio companies

Portfolio

6

Focus Areas

10

Top Stage

Phase 2

Investment Focus

Immunology Rare Disease Oncology Inflammatory Diseases Hematologic Malignancies Autoimmune Diseases Ophthalmology Genetics & Genomics Metabolic Cardiovascular

Portfolio Companies

Company	Stage	Valuation	Focus
Human Immunology Biosciences (HI-Bio)	phase-2	—	Immunology, Rare Disease
IFM Therapeutics (2)	Phase 2	—	Oncology, Inflammatory Diseases
Wugen	Phase 2	—	Oncology, Hematologic Malignancies
Myricx Bio	Pre-clinical	—	Oncology
Atsena Therapeutics	phase-1	—	Ophthalmology, Genetics & Genomics
Epetome	phase-1	—	Metabolic, Cardiovascular

Frequent Co-Investors

Brandon Capital1 shared Atlas Venture1 shared ARCH Venture Partners1 shared Novo Holdings1 shared Sofinnova Investments1 shared Lightstone Ventures1 shared Sofinnova Partners1 shared Omega Funds1 shared